<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588144</url>
  </required_header>
  <id_info>
    <org_study_id>IHanci</org_study_id>
    <nct_id>NCT02588144</nct_id>
  </id_info>
  <brief_title>Combined Stimulation of STN and SNr for Resistant Freezing of Gait in Parkinson's Disease</brief_title>
  <acronym>STN+SNr</acronym>
  <official_title>Combined Stimulation of Subthalamic Nucleus and Substantia Nigra Pars Reticulata for Resistant Freezing of Gait in Parkinson's Disease: A Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      54 patients with idiopathic Parkinson's disease and freezing of gait resistant to subthalamic
      nucleus stimulation and dopaminergic medication will be included into this multicentre
      randomised controlled double-blinded parallel group clinical trial. The treatment consists of
      two different stimulation settings using (i) conventional stimulation of the subthalamic
      nucleus [standard STN] as active comparator and (ii) combined stimulation of active electrode
      contacts located in both the subthalamic nucleus and substantia nigra pars reticulata
      [STN+SNr].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study is to investigate the efficacy and safety of combined
      [STN+SNr] stimulation by &quot;interleaving stimulation&quot; as compared to [standardSTN] after 3
      months on refractory freezing of gait (FOG). The Trial is designed as superiority study with
      an 80% power to detect a mean improvement of 4.7 points on the Freezing of Gait Assessment
      Course (Ziegler et al., 2010) with one-tailed P &lt; 0.2. To this end 54 patients will be
      studied. After a common baseline assessment in [standardSTN], patients will be randomized to
      either [standardSTN] or [STN+SNr] in 1:1 ratio (27 per arm). The primary endpoint assessment
      is scheduled 90 days from baseline assessment (V6). Additional interim visits are scheduled
      for secondary purpose from baseline at day 2 (V2), day 8 (V3), day 21 (V4), day 42 (V5).

      The rationale for this study comes from our previous phase II trial (Weiss et al., 2013) in
      which we have observed an improvement of freezing of gait from combined STN+SNr stimulation
      as secondary endpoint compared with standard STN stimulation at three-week follow-up.

      Secondary outcome measures include anamnestic assessments on freezing of gait and falls,
      balance, quality of life, neuropsychiatric symptoms and suicidality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freezing of Gait Assessment Course (FOG-AC)</measure>
    <time_frame>Outcome at day 90 (V6) with reference to baseline (V1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed Walking test from Core Assessment Program for Surgical Interventions in Parkinson's disease (CAPSIT-PD)</measure>
    <time_frame>At baseline, day 2, 8, 21, 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Scale</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's disease questionnaire (PDQ-39)</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait questionnaire</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's depression Inventory</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression scale</measure>
    <time_frame>At day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls diary</measure>
    <time_frame>At baseline, day 2, 8, 21, 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorders Society Unified Parkinson's disease Rating Scale (MDS-UPDRS III)</measure>
    <time_frame>At baseline, day 2, 8, 21, 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorders Society Unified Parkinson's disease Rating Scale (MDS-UPDRS II)</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement Disorders Society Unified Parkinson's disease Rating Scale (MDS-UPDRS IV)</measure>
    <time_frame>At baseline, day 42 and 90, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of Gait Assessment Course (FOG-AC)</measure>
    <time_frame>At baseline, day 2, 8, 21, 42 after active treatment (STN vs. STN+SNr), respectively</time_frame>
    <description>To determine treatment kinematics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>[standard STN]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: standard stimulation on subthalamic (STN) contacts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[STN+SNr]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>[standard STN]</intervention_name>
    <description>High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts</description>
    <arm_group_label>[standard STN]</arm_group_label>
    <other_name>subthalamic deep brain stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>[STN+SNr]</intervention_name>
    <description>high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation</description>
    <arm_group_label>[STN+SNr]</arm_group_label>
    <other_name>combined subthalamic and nigral stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's disease (according to the &quot;British Brain Bank criteria&quot;
             (Hughes, 1992) including genetic forms

          -  Therapy with STN-DBS (deep brain stimulation) (ACTIVA pulse generators) at least six
             months from surgery

          -  Activa PC (Primary Cell) or Activa RC (Rechargeable Cell) as implanted pulse generator
             with &quot;Interleaving&quot; programming option

          -  Localization of an active electrode contact in the subthalamic nucleus

          -  Localization of the caudal electrode contacts in the substantia nigra pars reticulata
             area (coordinates relative to midcommisural Point (MCP):

        left: -7mm ≤ x ≤ -12mm; -2mm ≤ y ≤ -6mm; -6mm ≤ z ≤ -10mm right: 7mm ≤ x ≤ 12mm; -2mm ≤ y ≤
        -6mm; -6mm ≤ z ≤ -10mm (x = medio-lateral, y = anterio-posterior, z = rostro-caudal)

          -  ≥ 30% improvement in UPDRS III with 'standard STN' compared to 'stimulation off' in
             dopaminergic off

          -  Freezing of Gait Assessment Course ≥10 and ≤33

          -  Patient not wheelchair-bound and possible to move self-dependently outside a freezing
             episode.

          -  Disease duration ≥ 5 years

          -  Age: between 18 and 80 years

          -  Dopaminergic medication constant for at least four weeks prior to study enrolment

          -  Written informed consent

        Exclusion Criteria:

          -  Participation in other clinical trials within the past three months and during
             enrolment in our study

          -  Cognitive impairment (Mini Mental State Exam &lt; 20)

          -  Suicidality, Psychosis

          -  Other severe pathological chronic condition that might confound treatment effects or
             interpretation of the data

          -  Pregnancy

          -  Paradoxical levodopa-induced &quot;on&quot; state freezing (Espay et al., 2012)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Neurodegenerative Diseases, Centre for Neurology, Tübingen, Germany, and Hertie-Institute for Clinical Brain Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alireza Gharabaghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Functional and Restorative Neurosurgery, Department of Neurosurgery, Tübingen, Germany, and Center for Integrative Neuroscience, Tübingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Weiss, MD</last_name>
    <phone>0049-7071-29-82340</phone>
    <email>daniel.weiss@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alireza Gharabaghi, MD</last_name>
    <phone>0049-7071-29-83550</phone>
    <email>alireza.gharabaghi@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center of Neurology and Hertie Institute for Clinical Brain Research, Department for Neurodegenerative Diseases and Neurosurgery University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Weiss, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Alireza Gharabaghi, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University Munich, Klinikum Großhadern, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Bötzel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jan Mehrkens, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg , Department for Neurology and Neurosurgery</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josephine Blume, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Max Lange, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Düsseldorf, Departments for Neurology and Neurosurgery</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfons Schnitzler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jan Vesper, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Köln, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Barbe, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Veerle Visser-Vandewalle, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weise, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dirk Winkler, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Kiel, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Falk, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Karsten Witt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charite- University Hospital Berlin, Departments for Neurology and Neurosurgery</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kühn, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gerd-Helge Schneider, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Pötter-Nerger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Wolfgang Hamel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Luxembourg, Department for Neurology and Neurosurgery</name>
      <address>
        <city>Luxembourg</city>
        <zip>L-4362</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rejko Krüger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Hertel, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Luxembourg</country>
  </location_countries>
  <results_reference>
    <citation>Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, Plewnia C, Bender B, Gharabaghi A, Wächter T, Krüger R. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial. Brain. 2013 Jul;136(Pt 7):2098-108. doi: 10.1093/brain/awt122. Epub 2013 Jun 11.</citation>
    <PMID>23757762</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2015</study_first_submitted>
  <study_first_submitted_qc>October 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Daniel Weiss</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>freezing of gait</keyword>
  <keyword>deep brain stimulation</keyword>
  <keyword>substantia nigra pars reticulata</keyword>
  <keyword>subthalamic nucleus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

